Recent Quotes

My Watchlist

Indicators

Immunome Inc (NQ: IMNM )

11.59 +0.12 (+1.05%)

Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	632,575
Open	11.81
Bid (Size)	11.57 (2)
Ask (Size)	11.60 (16)
Prev. Close	11.47
Today's Range	11.48 - 11.92
52wk Range	6.930 - 30.96
Shares Outstanding	60,054,372
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 01, 2024

From Immunome, Inc.

Via Business Wire

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

October 29, 2024

From Immunome, Inc.

Via Business Wire

Performance

YTD	+5.27%	+5.27%
1 Month	-13.70%	-13.70%
3 Month	-6.19%	-6.19%
6 Month	-25.03%	-25.03%
1 Year	+32.46%	+32.46%

More News

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

October 18, 2024

From Immunome, Inc.

Via Business Wire

Evaluating Immunome: Insights From 4 Financial Analysts

May 31, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session

October 11, 2024

Via Benzinga

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

October 08, 2024

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 08, 2024

From Immunome, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session

October 07, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session

October 01, 2024

Via Benzinga

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

September 13, 2024

From Immunome, Inc.

Via Business Wire

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

August 29, 2024

From Immunome, Inc.

Via Business Wire

Immunome Stock Sees RS Rating Jump To 91

August 20, 2024

Via Investor's Business Daily

IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024

August 12, 2024

Via InvestorPlace

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

August 12, 2024

From Immunome, Inc.

Via Business Wire

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

July 25, 2024

From Immunome, Inc.

Via Business Wire

Immunome Appoints Phil Tsai as Chief Technical Officer

June 27, 2024

From Immunome, Inc.

Via Business Wire

Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying

May 22, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session

May 21, 2024

Via Benzinga

Immunome Announces Completion of Purchase of Assets from Atreca

May 20, 2024

From Immunome, Inc.

Via Business Wire

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 17, 2024

From Immunome, Inc.

Via Business Wire

IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024

May 14, 2024

Via InvestorPlace

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024

From Immunome, Inc.

Via Business Wire

Immunome to Present at 2024 Bank of America Healthcare Conference

May 08, 2024

From Immunome, Inc.

Via Business Wire

Immunome Appoints Kinney Horn as Chief Business Officer

May 02, 2024

From Immunome, Inc.

Via Business Wire

Immunome Appoints Sandra M. Swain to Board of Directors

April 25, 2024

From Immunome

Via Business Wire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.